26 Result(s)

Article

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

P Kongtim, K Adekola, D R Milton, R Ramlal, A Jimenez, J Chen, G Rondon… in Leukemia (2017)

Article

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

While therapy-related (t)-myelodysplastic syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS prognostic models excluded t-MDS patients during devel...

A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres… in Leukemia (2017)

Article

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a clinical trial, we conducted a study for patients with...

G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju… in Leukemia (2017)

Article

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Z Chen, J E Cortes, J L Jorgensen, W Wang, C C Yin, M J You, E Jabbour… in Leukemia (2016)

Article

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

C D DiNardo, E Jabbour, F Ravandi, K Takahashi, N Daver, M Routbort, K P Patel… in Leukemia (2016)

Article

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are standard therapies for higher-risk (HR)-MDS, the r...

A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard… in Leukemia (2016)

Article

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110 patients (median age 70 years; range 27–89 years)...

N Daver, H Kantarjian, F Ravandi, E Estey, X Wang, G Garcia-Manero, E Jabbour… in Leukemia (2016)

Article

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero… in Leukemia (2014)

Article

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

P Jain, H Kantarjian, F Ravandi, D Thomas, S O'Brien, T Kadia, J Burger… in Leukemia (2014)

Article

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy

C D DiNardo, N Daver, N Jain, N Pemmaraju, C Bueso-Ramos, C C Yin, S Pierce… in Leukemia (2014)

Article

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

K Takahashi, E Jabbour, X Wang, R Luthra, C Bueso-Ramos, K Patel, S Pierce… in Leukemia (2013)

Article

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

The clinical features and outcomes of 148 patients with acute myeloid leukemia (AML) and 11q23 chromosomal abnormalities were compared with those of 2640 patients with non-11q23 AML. Patients with t(9;11) ), t...

Y Chen, H Kantarjian, S Pierce, S Faderl, S O'Brien, W Qiao, L Abruzzo… in Leukemia (2013)

Article

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance

The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intoler...

E Jabbour, P D le Coutre, J Cortes, F Giles, K N Bhalla, J Pinilla-Ibarz… in Leukemia (2013)

Article

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

Y Boumber, H Kantarjian, J Jorgensen, S Wen, S Faderl, R Castoro, J Autry… in Leukemia (2012)

Article

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

BCR–ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that...

E Jabbour, M Deininger, A Hochhaus in Leukemia (2011)

Article

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to at...

E Jabbour, A Hochhaus, J Cortes, P La Rosée, H M Kantarjian in Leukemia (2010)